|
|
|
Adalimumab
n=616
|
Certolizumab
n=21
|
Golimumab
n=48
|
Infliximab
n=1489
|
Natalizumab
n=3
|
Ustekinumabb
n=3
|
Vedolizumabc
n=15 |
|
Healthcare resource utilization
|
|
| Patients with an inpatient hospitalization, n (%) |
|
| Baseline |
|
|
126 (20.46) |
4 (19.05) |
11 (22.92) |
504 (33.85) |
1 (33.33) |
0 (0) |
1 (6.67) |
| Follow-up |
|
|
50 (8.12) |
1 (4.76) |
2 (4.17) |
172 (11.55) |
0 (0) |
1 (33.33) |
0 (0) |
| Inpatient hospitalizations per patient, mean (SD) |
|
|
| Baseline |
|
|
0.28 (0.62) |
0.24 (0.54) |
0.25 (0.48) |
0.47 (0.79) |
0.33 (0.58) |
0 (0) |
0.07 (0.26) |
| Follow-up |
|
|
0.10 (0.37) |
0.05 (0.22) |
0.06 (0.32) |
0.15 (0.46) |
0 (0) |
0.33 (0.58) |
0 (0) |
| Patients with an ED visit, n (%) |
|
|
| Baseline |
|
|
197 (31.98) |
6 (28.57) |
10 (20.83) |
638 (42.85) |
1 (33.33) |
0 (0) |
2 (13.33) |
| Follow-up |
|
|
133 (21.59) |
5 (23.81) |
9 (18.75) |
381 (25.59) |
0 (0) |
1 (33.33) |
2 (13.33) |
| ED visits per patient, mean (SD) |
|
|
| Baseline |
|
|
0.55 (1.01) |
0.52 (0.98) |
0.27 (0.57) |
0.72 (1.08) |
0.33 (0.58) |
0 (0) |
0.27 (0.80) |
| Follow-up |
|
|
0.28 (0.63) |
0.43 (0.93) |
0.19 (0.39) |
0.38 (0.82) |
0 (0) |
0.33 (0.58) |
0.20 (0.56) |
| Patients with outpatient visit, n (%) |
|
|
| Baseline |
|
|
615 (99.84) |
21 (100) |
48 (100) |
1483 (99.60) |
3 (100) |
3 (100) |
15 (100) |
| Follow-up |
|
|
613 (99.51) |
21 (100) |
48 (100) |
1486 (99.80) |
3 (100) |
3 (100) |
15 (100) |
| Outpatient visits per patient, mean (SD) |
|
|
| Baseline |
|
|
15.84 (10.48) |
15.52 (12.79) |
15.10 (11.66) |
17.22 (12.52) |
23.00 (12.53) |
16.67 (6.66) |
19.87 (10.60) |
| Follow-up |
|
|
15.35 (12.16) |
19.43 (16.19) |
15.29 (13.14) |
22.62 (12.56) |
32.00 (19.97) |
18.33 (9.45) |
26 (10.60) |
|
Costs, US$ 2015, mean (SD)
|
|
|
| Inpatient hospitalization costs per patient |
|
|
| Baseline |
|
|
5237.16 (22 173.03) |
2572.62 (5790.60) |
23 005.11 (140 362.91) |
9777.73 (25 098.06) |
2932.86 (5079.87) |
0 (0) |
865.41 (3351.72) |
| Follow-up |
|
|
1556.97 (6890.84) |
482.80 (2212.46) |
729.87 (3800.02) |
3283.48 (20 105.26) |
0 (0) |
2336.22 (4046.44) |
0 (0) |
| ED visit costs per patient |
|
|
| Baseline |
|
|
1038.43 (2343.31) |
780.88 (1975.45) |
490.31 (1365.25) |
1400.01 (3427.13) |
6829.45 (11 828.95) |
0 (0) |
369.12 (999.17) |
| Follow-up |
|
|
600.47 (1749.04) |
1528.11 (3226.87) |
351.29 (903.86) |
764.27 (2324.72) |
0 (0) |
253.86 (439.70) |
282.35 (943.82) |
| Outpatient visit costs per patient |
|
|
| Baseline |
|
|
6958.17 (12 328.91) |
7674.21 (9235.38) |
5884.37 (7294.03) |
10 125.67 (19 252.36) |
31 379.25 (19 129.65) |
4916.36 (2414.85) |
16 312.07 (21 577.52) |
| Follow-up |
|
|
4627.61 (6811.83) |
6128.68 (6785.56) |
3746.75 (4496.06) |
9033.33 (12 980.08) |
12 401.00 (2447.28) |
2645.23 (2211.82) |
34 620.88 (28 022.13) |
| Total medical costs per patient |
|
|
| Baseline |
|
|
15 092.62 (29 553.30) |
12 276.04 (11 549.75) |
31 145.25 (142 309.15) |
23 174.47 (32 421.13) |
41 152.04 (15 789.84) |
5276.74 (2135.49) |
18 866.09 (22 377.73) |
| Follow-up |
|
|
7774.36 (11 875.97) |
9022.00 (8764.70) |
5552.71 (7653.54) |
14 522.95 (26 152.63) |
12 559.75 (2518.88) |
5323.34 (5959.76) |
36 653.80 (30 519.07) |
| Pharmacy costs per patient |
|
|
| Baseline |
|
|
7656.26 (7809.05) |
7435.10 (6597.44) |
7738.25 (6266.00) |
6214.10 (6675.97) |
29 617.14 (12 089.04) |
2237.84 (3077.25) |
7942.91 (6995.66) |
| Follow-up |
|
|
48 591.53 (16 081.84) |
38 276.48 (9162.45) |
55 948.19 (11 963.48) |
45 710.70 (30 751.68) |
76 979.14 (16 852.84) |
53 905.11 (20 863.60) |
35 620.01 (54 465.94) |
| Medical and pharmacy costs per patient |
|
|
| Baseline |
|
|
22 748.88 (30 289.32) |
19 711.14 (13 912.50) |
38 883.50 (142 544.70) |
29 388.58 (33 327.49) |
70 769.18 (10 588.51) |
7514.57 (5168.32) |
26 809.01 (22 351.87) |
| Follow-up |
|
|
56 365.90 (21 357.74) |
47 298.48 (14 953.62) |
61 500.90 (14 444.79) |
60 233.64 (40 682.34) |
89 538.89 (19 025.45) |
59 228.45 (25 054.55) |
72 273.81 (46 912.99) |